Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)

A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Primary Objective:

To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM).

Secondary Objectives:

• To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm.
• To compare the Overall Survival (OS) between the two arms.
• To evaluate the Time To Progression (TTP) in each arm.
• To evaluate the PFS in high risk cytogenetic population in each arm.
• To evaluate the Duration of Response (DOR) in each arm.
• To evaluate the safety in both treatment arms.
• To determine the Pharmacokinetic profile of isatuximab in combination with pomalidomide.
• To evaluate the immunogenicity of isatuximab.
• To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.

Study Overview

• Status: Completed
• Conditions: Plasma Cell Myeloma
• Intervention / Treatment: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Isatuximab

Detailed Description

The duration of the study for the participants included a period for screening of up to 21 days (or up to 28 days for women who can become pregnant). Participants continued study treatment until disease progression, unacceptable adverse reaction, participants' wish or other reason of discontinuation.

During follow-up, participants who discontinued the study treatment due to progression of the disease were followed every 3 months (12 weeks) for survival (or until cut-off date), and participants who discontinued the study treatment prior to documentation of disease progression were followed-up every 4 weeks until disease progression, and then every 3 months (12 weeks) for survival (or until cut-off date).

• Study Type: Interventional
• Enrollment (Actual): 307
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • St Leonards, New South Wales, Australia, 2065
      • Investigational Site Number : 0360004
    • Waratah, New South Wales, Australia, 2298
      • Investigational Site Number : 0360001
  • Victoria
    • Melbourne, Victoria, Australia, 3000
      • Investigational Site Number : 0360005
    • Melbourne, Victoria, Australia, 3004
      • Investigational Site Number : 0360002
    • Richmond, Victoria, Australia, 3121
      • Investigational Site Number : 0360006
• Belgium
  • Antwerpen, Belgium, 2060
    • Investigational Site Number : 0560003
  • Brussel, Belgium, 1090
    • Investigational Site Number : 0560002
  • Gent, Belgium, 9000
    • Investigational Site Number : 0560004
  • Leuven, Belgium, 3000
    • Investigational Site Number : 0560001
• Canada
  • Quebec
    • Montreal, Quebec, Canada, H1T 2M4
      • Investigational Site Number : 1240001
    • Montreal, Quebec, Canada, H4A 3J1
      • Investigational Site Number : 1240004
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Investigational Site Number : 1240005
• Czechia
  • Brno, Czechia, 62500
    • Investigational Site Number : 2030005
  • Hradec Kralove, Czechia, 50005
    • Investigational Site Number : 2030004
  • Olomouc, Czechia, 77900
    • Investigational Site Number : 2030001
  • Ostrava - Poruba, Czechia, 70852
    • Investigational Site Number : 2030002
  • Praha 2, Czechia, 12808
    • Investigational Site Number : 2030003
• Denmark
  • Ålborg, Denmark, 9100
    • Investigational Site Number : 2080002
• France
  • Bayonne, France, 64100
    • Investigational Site Number : 2500021
  • Caen, France, 14033
    • Investigational Site Number : 2500008
  • Dijon, France, 21000
    • Investigational Site Number : 2500009
  • Grenoble, France, 38043
    • Investigational Site Number : 2500017
  • La Roche Sur Yon, France, 85925
    • Investigational Site Number : 2500013
  • Lille, France, 59037
    • Investigational Site Number : 2500003
  • Limoges, France, 87042
    • Investigational Site Number : 2500023
  • Montpellier Cedex, France, 34295
    • Investigational Site Number : 2500019
  • Nantes, France, 44093
    • Investigational Site Number : 2500002
  • POITIERS Cedex, France, 86021
    • Investigational Site Number : 2500007
  • Paris, France, 75005
    • Investigational Site Number : 2500015
  • Paris, France, 75743
    • Investigational Site Number : 2500016
  • Pessac, France, 33600
    • Investigational Site Number : 2500005
  • Pierre Benite, France, 69495
    • Investigational Site Number : 2500004
  • Reims, France, 51092
    • Investigational Site Number : 2500025
  • Rennes, France, 35033
    • Investigational Site Number : 2500014
  • TOULOUSE Cedex 9, France, 31059
    • Investigational Site Number : 2500001
  • Tours, France, 37044
    • Investigational Site Number : 2500012
  • Vandoeuvre-les-nancy, France, 54511
    • Investigational Site Number : 2500018
• Germany
  • Leipzig, Germany, 04103
    • Investigational Site Number : 2760001
• Greece
  • Athens, Greece, 11527
    • Investigational Site Number : 3000005
  • Athens, Greece, 11528
    • Investigational Site Number : 3000001
  • Athens, Greece, 106 76
    • Investigational Site Number : 3000002
  • Patra, Greece, 26504
    • Investigational Site Number : 3000004
  • Thessaloniki, Greece, 57010
    • Investigational Site Number : 3000003
• Hungary
  • Budapest, Hungary, 1083
    • Investigational Site Number : 3480001
  • Budapest, Hungary, 1097
    • Investigational Site Number : 3480003
  • Debrecen, Hungary, 4032
    • Investigational Site Number : 3480002
• Italy
  • Bologna, Italy, 40138
    • Investigational Site Number : 3800001
  • Catania, Italy, 95123
    • Investigational Site Number : 3800010
  • Firenze, Italy, 50134
    • Investigational Site Number : 3800009
  • Genova, Italy, 16132
    • Investigational Site Number : 3800008
  • Milano, Italy, 20132
    • Investigational Site Number : 3800007
  • Milano, Italy, 20133
    • Investigational Site Number : 3800002
  • Padova, Italy, 35128
    • Investigational Site Number : 3800006
  • Terni, Italy, 05100
    • Investigational Site Number : 3800004
  • Torino, Italy, 10126
    • Investigational Site Number : 3800003
• Japan
  • Aichi
    • Nagoya-shi, Aichi, Japan, 467-8602
      • Investigational Site Number : 3920001
  • Gunma
    • Shibukawa-shi, Gunma, Japan, 377-0280
      • Investigational Site Number : 3920005
  • Hokkaido
    • Sapporo-shi, Hokkaido, Japan, 060-8543
      • Investigational Site Number : 3920004
  • Kyoto
    • Kyoto-shi, Kyoto, Japan, 603-8151
      • Investigational Site Number : 3920006
  • Nagano
    • Suwa-shi, Nagano, Japan, 392-8510
      • Investigational Site Number : 3920008
  • Okayama
    • Okayama-shi, Okayama, Japan, 701-1192
      • Investigational Site Number : 3920003
  • Shizuoka
    • Sunto-gun, Shizuoka, Japan, 411-8777
      • Investigational Site Number : 3920007
  • Tokyo
    • Shibuya-ku, Tokyo, Japan, 150-8935
      • Investigational Site Number : 3920002
• Korea, Republic of
  • Incheon, Korea, Republic of, 21565
    • Investigational Site Number : 4100006
  • Seoul, Korea, Republic of, 06591
    • Investigational Site Number : 4100005
  • Jeollanam-do
    • Hwasun-gun, Jeollanam-do, Korea, Republic of, 58128
      • Investigational Site Number : 4100007
  • Seoul-teukbyeolsi
    • Seoul, Seoul-teukbyeolsi, Korea, Republic of, 03080
      • Investigational Site Number : 4100001
    • Seoul, Seoul-teukbyeolsi, Korea, Republic of, 06351
      • Investigational Site Number : 4100002
• New Zealand
  • Auckland, New Zealand, 2025
    • Investigational Site Number : 5540002
  • Auckland
    • Takapuna, Auckland, New Zealand, 1309
      • Investigational Site Number : 5540001
  • Otago
    • Dunedin, Otago, New Zealand, 9016
      • Investigational Site Number : 5540004
  • Waikato
    • Hamilton, Waikato, New Zealand, 3204
      • Investigational Site Number : 5540003
• Norway
  • Oslo, Norway, 0450
    • Investigational Site Number : 5780001
• Poland
  • Lubuskie
    • Lublin, Lubuskie, Poland, 20-081
      • Investigational Site Number : 6160003
  • Malopolskie
    • Krakow, Malopolskie, Poland, 31-501
      • Investigational Site Number : 6160005
  • Mazowieckie
    • Warszawa, Mazowieckie, Poland, 02-776
      • Investigational Site Number : 6160001
  • Slaskie
    • Chorzow, Slaskie, Poland, 41-500
      • Investigational Site Number : 6160002
• Portugal
  • Coimbra, Portugal, 3000-075
    • Investigational Site Number : 6200004
  • Lisboa, Portugal, 1070
    • Investigational Site Number : 6200002
  • Porto, Portugal, 4200
    • Investigational Site Number : 6200001
• Russian Federation
  • Moscow, Russian Federation, 125167
    • Investigational Site Number : 6430004
  • Moscow, Russian Federation, 125284
    • Investigational Site Number : 6430001
  • Moscow, Russian Federation, 129301
    • Investigational Site Number : 6430002
• Slovakia
  • Bratislava, Slovakia, 83310
    • Investigational Site Number : 7030001
• Spain
  • Madrid, Spain, 28006
    • Investigational Site Number : 7240003
  • Salamanca, Spain, 37007
    • Investigational Site Number : 7240004
  • A Coruña [La Coruña]
    • Santiago de Compostela, A Coruña [La Coruña], Spain, 15706
      • Investigational Site Number : 7240005
  • Barcelona [Barcelona]
    • Barcelona, Barcelona [Barcelona], Spain, 08035
      • Investigational Site Number : 7240001
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Investigational Site Number : 7240006
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Investigational Site Number : 7240002
• Sweden
  • Luleå, Sweden, 97180
    • Investigational Site Number : 7520004
  • Uddevalla, Sweden, 451 80
    • Investigational Site Number : 7520005
• Taiwan
  • Kaohsiung, Taiwan, 833
    • Investigational Site Number : 1580004
  • Taichung, Taiwan, 40447
    • Investigational Site Number : 1580002
  • Taipei, Taiwan, 100
    • Investigational Site Number : 1580001
  • Taoyuan, Taiwan, 333
    • Investigational Site Number : 1580003
• Turkey
  • Ankara, Turkey, 06620
    • Investigational Site Number : 7920001
  • Antalya, Turkey, 07050
    • Investigational Site Number : 7920002
  • Istanbul, Turkey, 34010
    • Investigational Site Number : 7920005
  • Istanbul, Turkey, 34381
    • Investigational Site Number : 7920006
  • Istanbul, Turkey, 34390
    • Investigational Site Number : 7920003
  • Istanbul, Turkey
    • Investigational Site Number : 7920004
  • Izmir, Turkey, 35040
    • Investigational Site Number : 7920008
  • Izmir, Turkey, 35340
    • Investigational Site Number : 7920010
  • Kayseri, Turkey, 38039
    • Investigational Site Number : 7920009
  • Kocaeli, Turkey, 41400
    • Investigational Site Number : 7920007
• United Kingdom
  • London, City Of
    • London, London, City Of, United Kingdom, EC1A 7BE
      • Investigational Site Number : 8260002
    • London, London, City Of, United Kingdom, SE1 9RT
      • Investigational Site Number : 8260003
    • London, London, City Of, United Kingdom, WC1E6AG
      • Investigational Site Number : 8260001
• United States
  • Florida
    • Plantation, Florida, United States, 33324
      • BRCR Medical Center Inc. Site Number : 8400002
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Site Number : 8400006

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria :

• Age superior or equal to 18 years or country's legal age of majority if the legal age was superior to 18 years old.
• Participants had a documented diagnosis of multiple myeloma with evidence of measurable disease i.e. serum M protein superior or equal to 0.5 grams per decilitre (g/dL) measured using serum protein immunoelectrophoresis and or urine M protein superior or equal to 200 mg per 24 hours measured using urine protein immunoelectrophoresis.
• Participants had received at least 2 prior lines of anti-myeloma therapy, which must include at least 2 consecutive cycles of lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.
• Participants had failed treatment with lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) alone or in combination (Intolerant, progression within 6 months after reaching Partial Response or better).
• Participants had progressed on or within 60 days after end of previous therapy before to study entry, i.e., refractory to the last line of treatment.

Exclusion criteria:

• Primary refractory multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.
• Free Light Chain measurable disease only.
• Prior therapy with pomalidomide.
• Any anti-myeloma drug treatment within 14 days before randomization, including dexamethasone.
• Eastern Cooperative Oncology Group performance status superior to 2.
• Platelets inferior to 75 000 cells per microliter (mcL) if inferior to 50% of bone marrow (BM) nucleated cells are plasma cells, and inferior to 30 000 cells per mcL if superior or equal to 50% of BM nucleated cells are plasma cells. Platelet transfusion was not allowed within three days before the screening visit.
• Absolute neutrophil count inferior to 1000 per mcL (1*10^9/L).
• Creatinine clearance inferior to 30 mL per minute (Modification of Diet in Renal Disease [MDRD] Formula).
• Total bilirubin superior to 2*ULN (Upper Limit of Normal).
• Corrected serum calcium superior to 14 milligrams per deciliter (mg/dL) (superior to 3.5 millimoles per liter (mmol/L).
• Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) superior to 3*ULN.
• Hypersensitivity to immunomodulatory drugs (IMiDs) (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.
• Hypersensitivity to dexamethasone, sucrose histidine (as base and hydrochloride salt), and polysorbate 80 or any of the components of study therapy that are not amenable to premedication with steroids, or H2 blockers that would prohibit further treatment with these agents.
• Significant cardiac dysfunction; myocardial infarction within 12 months; unstable, poorly controlled angina pectoris.
• Pregnant or breastfeeding woman or female who intends to become pregnant during the participation in the study.
• Male participants who disagreed to practice true abstinence or disagreed to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and at least 3 or 5 months following study treatment discontinuation, even if he had undergone a successful vasectomy.
• All participants who disagreed to refrain from donating blood while on study treatment and for 4 weeks after discontinuation from this study treatment.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Pd (pomalidomide + dexamethasone); Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 306.6 weeks).	Drug: Pomalidomide; Pharmaceutical form: capsule Route of administration: oral; Other Names: POMALYST IMNOVID; Drug: Dexamethasone; Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Experimental: IPd (isatuximab + pomalidomide + dexamethasone); Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 311.0 weeks).	Drug: Pomalidomide; Pharmaceutical form: capsule Route of administration: oral; Other Names: POMALYST IMNOVID; Drug: Dexamethasone; Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous; Drug: Isatuximab; Pharmaceutical form: solution for infusion Route of administration: intravenous; Other Names: SAR650984; Sarclisa

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	PFS:time from date of randomization to date of first documentation of progressive disease (PD) determined by Independent Response Committee (IRC) or date of death from any cause, whichever comes first. If progression or death was not observed, participant was censored at date of last progression-free tumor assessment prior to study cut-off date. Analysis was performed by Kaplan-Meier method. PD as per International Myeloma Working Group (IMWG) criteria was defined as increase of >=25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be >=0.5gram(g)/dL), serum M-protein increase >=1g/dL if lowest M component was >=5g/dL; urine M-component (absolute increase must be >=200mg/24hour), appearance of new lesion(s),>=50% increase from nadir in sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in the longest diameter of a previous lesion >1 centimeter in short axis.	From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival in High Risk Cytogenetic Population	PFS in high risk cytogenetic population was defined as PFS in subgroup of participants carrying high risk cytogenetic changes including del(17p), translocation (t)(4;14) or translocation t(14;16) assessed by fluorescence in situ hybridization (FISH). PFS was defined as the time from date of randomization to date of first documentation of PD (determined by IRC) or date of death from any cause, whichever comes first. PD defined as per IMWG criteria as: increase of >=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be >=0.5 g/dL), serum M-protein increase >=1 g/dL if lowest M component was >=5 g/dL; urine M-component (absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in the longest diameter of previous lesion >1 centimeter (cm) in short axis.	From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)	CEOI was defined as the plasma concentration at end of infusion.	End of infusion on Cycle(C)1 Day(D)1 and Cycle1 Day 15; Cycle 2 Day 1; and Cycle 4 Day 1
Pharmacokinetic Parameter: Accumulation Ratio of Isatuximab at Concentration at the End of Infusion (CEOI)	Accumulation Ratio was defined as the ratio of CEOI of Cycle 2 Day 1 versus Cycle 1 Day 1 and Cycle 4 Day 1 versus Cycle 1 Day 1, where CEOI was the plasma concentration at the end of infusion.	End of infusion on Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 4 Day 1
Pharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)	CEOI+1 hour was defined as the plasma concentration of isatuximab at 1 hour after end of infusion.	Cycle 1:1 hour after End of Infusion on Day 1; Cycle 4:1 hour after End of Infusion on Day 1
PK Parameter: Accumulation Ratio of Isatuximab at Trough Concentration (Ctrough)	Accumulation Ratio was defined as the ratio of Ctrough of Cycle 2 Day 1 versus Cycle 1 Day 8 and Cycle 4 Day 1 versus Cycle 1 Day 8, where Ctrough is the concentration prior to study drug administration.	Pre-infusion on Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 4 Day 1
Number of Participants With Anti-drug Antibodies (ADA)	ADA were categorized as: pre-existing, treatment induced and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment and post-treatment.	From randomization up to 60 days after last dose of study drug (maximum duration 76.7 weeks)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score	EORTC-Quality of Life Questionnaire (QLQ)-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. EORTC QLQ-C30 included GHS/ QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.	Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score	EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Disease symptoms domain is one of the four domain scores. Disease symptoms domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL	Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment Domain Score	EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.	Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value	The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.	Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS)	EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.	Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Number of Participants With Minimal Residual Disease (MRD)	MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR, to determine the depth of response at the molecular level. IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow aspirates. MRD was classified as positive or negative at the minimum sensitivity of 1 in 10^5 nucleated cells. MRD negativity was defined as the absence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening. MRD positivity was defined as the presence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening.	Up to 76.7 weeks
Overall Response Rate (ORR): Percentage of Participants With Disease Response as Per Independent Response Committee (IRC)	ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response, assessed by IRC. sCR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates plus normal free light chain(FLC)ratio(0.26-1.65), absence of clonal cells in bone marrow biopsy.CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates.VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: >=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h,if present at baseline,>=50% reduction in the size (SPD) of soft tissue plasmacytomas.	From the date of randomization to the date of first documentation of progression or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Percentage of Participants With Best Overall Response (BOR) as Per Independent Response Committee	BOR:best sequential response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/data cut-off, whichever comes first. Ordering of evaluations from best to worse was: sCR,CR,VGPR,PR, minimal response (MR), stable disease (SD), PD, and not evaluable.CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates. sCR:CR as defined previously plus normal FLC ratio (0.26 to 1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum and urine M-protein detectable by immunofixation,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: >=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h. MR:>=25% but <=49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%. SD: Not meeting criteria for CR,VGPR,PR,MR/PD.	From the date of randomization until disease progression, or death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Per Independent Response Committee	VGPR rate was defined as the percentage of participants achieving a VGPR or better as BOR. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein plus urine M-protein level <100 mg/24 h or >=90% decrease in the sum of maximal perpendicular diameter compared to baseline in soft tissue plasmacytoma. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates.	From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment, or data cut-off whichever comes first (maximum duration 76.7 weeks)
Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee	CBR was defined as the percentage of participants achieving a MR or better as BOR. MR was defined as >= 25% but <= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceed 200 mg/24h; if present at baseline, >=50% reduction in size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.	From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Overall Survival (OS): Final Analysis	OS was defined as the time from the date of randomization to death from any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive or at the cut-off date, whichever comes first. This pre-specified final analysis was performed when the 220 OS events were met.	From the date of randomization to date of death from any cause or data cut-off date, whichever was earlier (maximum duration 245.6 weeks)
Time to Progression (TTP) as Per Independent Response Committee	TTP was defined as time from randomization to the date of first documentation of PD, as determined by the IRC. As per IMWG criteria, PD was defined for participants with increase of >= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be >= 0.5 g/dL), serum M-protein increase >=1 g/dL if the lowest M component was >=5 g/dL; urine M-component (the absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in the longest diameter of a previous lesion >1 centimeter in short axis.	From the date of randomization to the date of first documentation of progression, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Duration of Response (DOR) as Per Independent Response Committee	DOR:time from date of first IRC determined response(PR or better) to date of first IRC-PD or death, whichever occurred first.DOR was determined only for participants who had achieved a response of PR or better based on disease assessment by IRC.If progression or death was not observed,participant was censored at date of participants last progression-free tumor assessment prior to initiation of further anti-myeloma treatment(if any)and study cut-off date. PD(IMWG criteria):increase of >=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be >=0.5 g/dL), serum M-protein increase >=1g/dL if lowest M component was >=5g/dL;urine M-component (absolute increase must be >=200mg/24 hour),appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion,or >=50% increase in the longest diameter of a previous lesion >1 cm in short axis. PR:>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h.	From the date of the first IRC determined response to the date of first IRC progression or death, whichever occurred first (maximum duration 76.7 weeks)
Time to First Response (TT1R) as Per Independent Response Committee	TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. PR was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.	From the date of randomization to the date of first IRC determined response, or death or data cut-off whichever comes first (maximum duration 76.7 weeks)
Time to Best Response (TTBR) as Per Independent Response Committee	TTBR was defined as the time from randomization to the date of first occurrence of IRC determined BOR (PR or better) that was subsequently confirmed. PR was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.	From the date of randomization to date of first occurrence of IRC determined best overall response or data cut-off whichever comes first (maximum duration 76.7 weeks)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened (according to the Investigator opinion), or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.	From randomization up to 30 days after last dose of study drug (maximum duration up to 241.6 weeks for Pd arm and 245.6 weeks for IPd arm)
PK Parameter: Plasma Concentration of Isatuximab at Ctrough	Trough Concentration (Ctrough) is the concentration prior to study drug administration.	Pre-infusion on C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1; End of treatment (EOT [30 days after last drug administration])

Collaborators and Investigators

• Sponsor: Sanofi
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

General Publications

• Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S, Suzuki K; ICARIA-MM study group. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8.
• Wilmoth J, Colson K, Dubin F, Kellam C. Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma. Clin J Oncol Nurs. 2021 Dec 1;25(6):706-712. doi: 10.1188/21.CJON.706-712.
• Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.
• Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450. No abstract available.
• Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Mace S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum In: Lancet. 2019 Dec 7;394(10214):2072. doi: 10.1016/S0140-6736(19)32944-7.
• Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10. Erratum In: Lancet Oncol. 2022 Apr;23(4):e161. doi: 10.1016/S1470-2045(22)00131-0. Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00493-4.

Study record dates

Study Major Dates

• Study Start (Actual): December 22, 2016
• Primary Completion (Actual): November 22, 2018
• Study Completion (Actual): November 1, 2023

Study Registration Dates

• First Submitted: December 4, 2016
• First Submitted That Met QC Criteria: December 8, 2016
• First Posted (Estimated): December 13, 2016

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 16, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Anti-CD38 monoclonal antibody
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Dexamethasone; Pomalidomide
• Other Study ID Numbers: EFC14335; 2016-003097-41 (EudraCT Number); U1111-1180-6262 (Registry Identifier: ICTRP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes